# The GPR30 agonist G-1 promotes hair growth via Wnt/Hedgehog signaling in mice

## TL;DR

This study shows that activating the GPR30 receptor with G-1 promotes hair growth in mice by boosting key signaling pathways.

## Contribution

The study identifies GPR30 as a novel therapeutic target for estrogen-mediated hair loss through Wnt/Hedgehog signaling.

## Key findings

- GPR30 is highly expressed in mouse skin during the anagen phase of hair growth.
- G-1 activates GPR30, enhancing Wnt/Hedgehog signaling in mouse and human hair follicles.
- GPR30 deficiency or antagonism blocks G-1's effects, confirming its essential role in hair growth.

## Abstract

GPR30 is a membrane-associated receptor involved in rapid, non-genomic estrogen signaling. Estrogen significantly influences hair growth and susceptibility to hair loss, with differences primarily driven by hormonal factors. While estrogen’s role in regulating hair follicle cycling is recognized, its precise molecular mechanisms remain unclear. This study investigates the role of GPR30 in hair follicle biology and evaluates its potential as a therapeutic target for estrogen-mediated hair loss disorders.

The GPR30 selective agonist G-1 was administrated to female Gpr30-deficient mice with a C57BL/6J background and human hair follicle dermal papilla cell, and the effects on hair growth and the molecular signaling were evaluated.

We demonstrate that GPR30 is abundantly expressed in mouse skin, particularly during the anagen phase of the hair follicle cycle, implicating it in hair growth regulation. Activation of GPR30 using the selective agonist G-1 in mouse skin and human dermal papilla cells significantly upregulated Wnt/Hedgehog signaling, which are key pathways promoting hair growth. These effects were absent in Gpr30-deficient mice or in those administered a GPR30 antagonist, confirming the essential role of GPR30 in estrogen-mediated regulation of hair follicle activity.

Our findings underscore the importance of GPR30 in modulating hair growth and suggest that GPR30, along with its selective agonists, holds promise as a novel therapeutic target for treating hair loss disorders and other estrogen-responsive conditions.